Radiopharmaceutical developer and isotope manufacturer for targeted oncology
ITM develops and manufactures radioisotope-based therapeutics and diagnostics for hard-to-treat cancers, with a GMP-grade stack spanning LabWare LIMS, Chromeleon, MassHunter and the Veeva Vault quality suite. Its hiring is engineering-heavy and accelerating, centered on industrial automation (Beckhoff TwinCAT 3, Siemens TIA Portal, WinCC, KUKA) and OT network integrity, which points to a production-capacity buildout rather than pure R&D growth.
ITM Isotope Technologies Munich SE is a public radiopharmaceutical company headquartered in Garching near Munich, Bavaria, founded in 2004. It produces medical radioisotopes and pairs them with targeting molecules to build a precision oncology pipeline that includes Phase 3 programs. The company serves cancer patients, clinicians and pharma partners, and runs development, manufacturing and global supply operations. It employs 501–1,000 people, and current hiring is concentrated in Germany. Business systems run on SAP S/4HANA, SAP SuccessFactors and Veeva CRM.
ITM runs SAP S/4HANA, SAP SuccessFactors and Veeva Vault for business and quality, LabWare LIMS, Chromeleon and MassHunter in labs, and Siemens TIA Portal, WinCC, Beckhoff TwinCAT 3 and KUKA for plant automation.
Yes. Hiring is accelerating and engineering-led, focused on automation software for special machines, virtual commissioning, OT network maintenance and plant construction projects in Germany.
ITM is headquartered in Garching near Munich, Bavaria, Germany. It was founded in 2004 and has 501–1,000 employees.
Other companies in the same industry, closest in size
ITM Isotope Technologies Munich SE's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.